Viking Therapeutics, Inc. (NASDAQ: VKTX) Starts Presentation at 29th Annual Roth Conference
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of Type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective…







